Cancer has traditionally been perceived as a disease attributable to the accumulation of genetic abnormalities.
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Histone Deacetylase Inhibition in Hematological Malignancies
Cancer has traditionally been perceived as a disease attributable to the accumulation of genetic abnormalities. 1 Recent research has identified the additional, prominent role of epigenetics in cancer pathogenesis. Epigenetic modifications differ from genetic mutations as they are largely reversible, covalent alterations of DNA or histone proteins. Still, they exert a dominant effect on chromatin structure and signaling, thus strongly influencing gene expression. Our understanding of the cancer epigenome is rapidly expanding due to advances in genomic techniques. As the principal regulatory components defining the epigenome are enzymes, an opportunity exists to develop targeted therapies. An emerging class of epigenetic cancer therapeutics is defined by the inhibitors of histone deacetylase (HDAC)
proteins. HDAC inhibitors have already demonstrated a clinical utility in the treatment of advanced cutaneous T-cell lymphoma (CTCL). Basic and
translational research has identified a compelling activity of these agents beyond CTCL, beyond cancer, and beyond even epigenetics. 
Acetylation-A Dynamic Regulatory Process
Acetylation is a type of post-translational modification that can induce structural and conformational changes in proteins in a manner analogous to phosphorylation. Much as kinases and phosphatases regulate the phosphorylation state of proteins, acetyltransferases and HDACs regulate their acetylation state. 3 For example, lysine acetylation is analogous to tyrosine phosphorylation in that both modifications are reversible and have functional consequences linked to disease biology in cancer: tyrosine autophosphorylation of the Abl kinase is causally linked to the development of chronic myeloid leukemia, while de-acetylation of the amino-terminal tail of histone proteins is linked to gene silencing in many cancers. As suggested by the name given to this class of proteins, the first deacetylases were found to act on histones, the round octomeric protein complexes tightly packaging DNA into nucleosomes. 4 More recently, a variety of other proteins have been identified that undergo reversible acetylation, including tubulin, 5 p53, 6 and Hsp90. 7 As each of these proteins is a validated target in cancer, inhibitors capable of modulating the protein acetylation state have become highly desirable.
HDACs and HDAC Inhibitors-History and Biology
The discovery of human HDACs illustrates the success of forward chemical genetics, a discovery process in which the biological activity of a small molecule leads to the identification of the cellular target and, when compelling, the optimization of a therapeutic. Trichostatin A is a natural substance that was found in 1987 to potently arrest growth and induce differentiation of leukemia cells. 8 Linking this antitumor activity to the induction of histone hyperacetylation three years later 9 sparked an interest in developing HDAC inhibitors as potential chemotherapeutics. However, the chemical optimization of trichostatin and other natural product inhibitors required the identification of the mammalian target protein, which proved elusive for several years. A breakthrough came in 1996 with the purification and characterization of the first human HDAC (HDAC1) by the laboratory of Stuart Schreiber. 10 The Schreiber laboratory was studying a structurally similar molecule, trapoxin, which was found to induce substantial phenotypic changes in cultured cancer cells. After chemically coupling trapoxin to an affinity matrix, the first human HDACs were pulled down, purified, and characterized as master regulators of gene expression. In the years that followed, additional HDACs were discovered, now defining a family of 18 enzymes divided into four classes by structure and function. 
Pathways Through Which HDAC Inhibitors Affect Cancer Growth
The specific substrate proteins targeted by HDACs and thus affected by HDAC inhibitors are incompletely understood. Still, HDACs have been linked to a number of fundamental cancer processes (see Table 1 ).
Cell-cycle Arrest and Differentiation
Even prior to the identification of the cellular target, HDAC inhibitors have been known to arrest cells at the G1/S transition of the cell-cycle, allowing subsequent differentiation. This has largely been linked to the increased expression of p21WAF1, reducing phosphorylation of pRb.
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Repression of Pro-apoptotic Proteins
The best-characterized function of HDACs is their ability to repress transcriptional activity. HDAC inhibition has been linked to the de-repression of pro-apoptotic factors, including Fas, tumor necrosis factor-alpha-related apoptosis-inducing ligand, and death receptor 5. 15 Importantly, HDAC inhibitors have also been identified as activating the transcription of other target genes, suggesting that direct inhibition of co-repressor complexes is also accompanied by global alterations of chromatin structure, leading to activation or repression by other cis-regulatory elements.
Regulation of Hsp90 Activity
Hsp90 is a chaperone protein responsible for the proper folding and stabilization of a number of proteins, including oncogenic and anti-apoptotic factors.
Researchers have recently shown that Hsp90 can be deacetylated by HDAC6, measurably affecting Hsp90 activity. 13 Inhibition of HDAC6 leads to Hsp90 acetylation and degradation of anti-apoptotic and pro-survival Hsp90-client proteins, including mutant FMS-like tyrosine kinase 3, Bcr-Abl, AKT, and c-Raf. 
HDAC Inhibitors as Single-agent Drugs-Variation on a Theme
With an industry-wide interest in developing HDAC inhibitors as drugs, a structural theme has emerged among lead compounds, which thus far target only class I, II, and IV enzymes. HDAC inhibitors possess three distinct elements:
a chelation feature that binds to catalytic zinc at the active site; an aliphatic or 19, 20 The clinical potential of LBH589 has been suggested in a phase I study in patients with advanced CTCL. 21 An interim analysis of FK228 suggests activity in CTCL and relapsed peripheral TCL. 22 Higher potency agents such as these display markedly enhanced in vitro antineoplastic activity, but tolerability in large
cohorts has yet to be determined. In particular, a key challenge for HDAC inhibitors concerns prolongation of cardiac repolarization, drug-induced torsades de pointes and sudden cardiac death. 23 Consequently, electrocardiographic monitoring is an essential component of pre-clinical and post-marketing studies and use in patients with underlying structural heart disease or dysrhythmia, or in patients who are taking QT-prolonging drugs, should be avoided.
HDAC Inhibitors in Combination Chemotherapeutics
HDAC inhibitors display potent antineoplastic activity as single agents in a variety of disease models. However, the use of HDAC inhibitors in combination with pre-existing chemotherapies appears to be the most promising application beyond hematological malignancies. A few promising combinations are currently in clinical trials, based on mechanistic hypotheses.
A particularly illustrative example is the combination of certain HDAC inhibitors with bortezomib in multiple myeloma. The proteasome inhibitor bortezomib is 28 Other studies have suggested that HDAC inhibitors may also improve learning and memory. 29 Disparities between the deacetylases of micro-organisms also establish the feasibility of developing well-tolerated, antimicrobial deacetylase inhibitors.
In summary, deacetylases have emerged as appealing, tractable targets for therapeutic discovery and development in cancer. As the cellular biology of HDAC protein function unfolds and as second-generation, isoform-selective inhibitors are brought forward as therapeutics, we can expect a broad and meaningful clinical impact. ■
